Shanghai Fosun Pharmaceutical (SHA:600196) subsidiary Henlius signed a licensing agreement with Dr. Reddy's to develop, produce, and commercialize HLX15 in the US and 42 European countries, including the UK and Switzerland.
HLX15 is a biosimilar of Daratumumab and is intended to treat multiple myeloma, according to a Thursday filing with the Shanghai bourse.
The deal includes an upfront payment of $33 million and potential milestone payments of up to $98.6 million yuan.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。